Bruce E. Scott serves as Independent Director of the Company. He has served as a director of Omnicell since May 2019. From April 2014 to November 2018, Mr. Scott served as President of the EnvisionPharmacies division of EnvisonRxOptions, a health care and pharmacy benefit management company and a subsidiary of the Rite Aid Corporation. From September 2008 to April 2012, Mr. Scott held various executive roles at Medco Health Solutions, Inc., a pharmacy benefit management company, including President of Accredo Infusion Services, President of Critical Care Systems and Senior Vice President and Chief Pharmacist. From 2004 to July 2008, Mr. Scott was Chief Operating Officer of McKesson Medication Management LLC, a provider of pharmacy management services. Previously, he held several senior leadership roles at Allina Hospitals and Clinics, including as the Director of Pharmacy of United Hospital from 1987 to 1998. Mr. Scott serves as Chair of the University of Wisconsin, School of Pharmacy Board of Visitors, an advisory board for the School of Pharmacy. Mr. Scott received a B.S. in pharmacy from the University of Wisconsin and an M.S. in pharmacy administration from the University of Kansas where he also completed a pharmacy residency program.
As the Independent Director of Omnicell, the total compensation of Bruce Scott at Omnicell is $380,820. There are 10 executives at Omnicell getting paid more, with Randall Lipps having the highest compensation of $7,208,970.
Bruce Scott is 64, he's been the Independent Director of Omnicell since 2019. There are 3 older and 13 younger executives at Omnicell. The oldest executive at Omnicell, Inc. is Sara White, 74, who is the Independent Director.
Bruce's mailing address filed with the SEC is OMNICELL, INC., 4220 NORTH FREEWAY, FORT WORTH, TX, 76137.
Over the last 22 years, insiders at Omnicell have traded over $118,258,750 worth of Omnicell stock and bought 526,030 units worth $5,215,749 . The most active insiders traders include William H Jr Younger, Randall A Lipps y Benjamin A Horowitz. On average, Omnicell executives and independent directors trade stock every 10 days with the average trade being worth of $482,255. The most recent stock trade was executed by Christine Marie Mellon on 9 June 2023, trading 7,951 units of OMCL stock currently worth $581,536.
since 1992, omnicell has been creating new efficiencies to improve patient care, anywhere it is delivered. omnicell is a leading supplier of comprehensive automation and business analytics software for patient-centric medication and supply management across the entire health care continuum—from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. omnicell’s automated hardware/software systems for medication dispensing include solutions from the point of entry into the hospital through the central pharmacy, nursing unit, operating room, and patient bedside. our supply management systems promote greater cost control and charge capture for payer reimbursement, and improve management and reordering of inventory. omnicell® products range from high-security, closed-cabinet systems and software to open-shelf and combination systems in the nursing unit, cath lab, and operating room. more than 3,200 customers worldwide have utilized omnice
Omnicell executives and other stock owners filed with the SEC include: